Table 1. Demographic data and baseline tumour characteristics.
| ROS1 positive number (%) | ROS1 negative number (%) | |
|---|---|---|
| Number of patients | 22 | 513 |
| Median age | 54 | 60 |
| Gender | ||
| • Male | 13 (60%) | 372 (72%) |
| • Female | 09 (40%) | 141 (28%) |
| Smoking history | 03 (13%) | 240 (47%) |
| Co-morbidities | ||
| • Hypertension | 07 (31%) | 123 (24%) |
| • Diabetes Mellitus | 04 (18%) | 95 (18%) |
| Stage of disease | ||
| • Stage III | 1 (5%) | 22 (4%) |
| • Stage IV | 21 (95%) | 491 (96%) |
| Median number of metastatic sites | 2 | 2 |
| • Opposite lung | 11 (50%) | 265 (52%) |
| • Brain metastasis | 2 (9%) | 71 (14%) |
| • Pleural effusion | 9 (40%) | 231 (45%) |
| • Liver | 2 (9%) | 70 (14%) |
| • Adrenals | 6 (27%) | 51 (10%) |
| • Bones | 8 (36%) | 154 (30%) |
| Procurement of crizotinib n = 16 | ||
| Self, no insurance | 7 (44%) | |
| Self, insurance | 4 (25%) | |
| Sponsored by NGO | 5 (31%) | |